Literature DB >> 27002465

Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.

Heidi Theeten1, Catharina Mathei2, Kelly Peeters1, Benson Ogunjimi1,3, Herman Goossens1, Margareta Ieven1, Pierre Van Damme1, Nathalie Cools1.   

Abstract

Morbidity and mortality in the elderly are associated with viral infections, including influenza and cytomegalovirus (CMV). With increasing age, cellular immunity gains importance in protection to influenza, but latent CMV is highly prevalent and associated with immune dysfunction. An insight into the association between immunity against influenza and CMV adds to the understanding of healthy aging. Here we first aimed to measure influenza-specific cellular immunity using granzyme B (GrzB) and interferon-gamma (IFN-γ)-ELISpot. Next, influenza-specific cellular immunity was associated with humoral and cellular CMV-specific immunity in healthy 65+ elderly. Vaccine trial participants gave additional blood samples 3 weeks after receiving a H1N1 containing vaccine. CMV serology was determined and peripheral blood mononuclear cells were stimulated with influenza N1 or CMV pp65-derived peptide pools for 7 days and rechallenged to assess antigen-specific GgrzB and IFN-γ responses using ELISpot assays. Results were compared using chi-square and correlation analysis. Eighty-three individuals (60% men, 65% CMV IgG+, age range 65-78y) participated. We found significant positive associations between IFN-γ and GrzB responses to both influenza and CMV, but also between a positive CMV serostatus and an influenza N1-specific activation marker response (p = 0.013). CMV pp65 responses were detected in CMV IgG+ individuals, but remarkably also in CMV IgG- individuals (27%). In this study, following influenza vaccination, elderly with cellular immunity against CMV were more likely to have cellular immunity against influenza vaccine N1 antigen. These findings stress the need to continue exploring the possible role of CMV in immunosenescence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27002465      PMCID: PMC4827302          DOI: 10.1089/vim.2015.0071

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  44 in total

1.  Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Authors:  Giovanni Della Cioppa; Uwe Nicolay; Kelly Lindert; Geert Leroux-Roels; Frederic Clement; Flora Castellino; Grazia Galli; Nicola Groth; Giuseppe Del Giudice
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

2.  Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Authors:  Zoe Moodie; Leah Price; Sylvia Janetzki; Cedrik M Britten
Journal:  Methods Mol Biol       Date:  2012

3.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

4.  Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities.

Authors:  Wendy P J den Elzen; Ann C M T Vossen; Herman J M Cools; Rudi G J Westendorp; Aloys C M Kroes; Jacobijn Gussekloo
Journal:  Vaccine       Date:  2011-04-15       Impact factor: 3.641

5.  Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides.

Authors:  F Kern; N Faulhaber; C Frömmel; E Khatamzas; S Prösch; C Schönemann; I Kretzschmar; R Volkmer-Engert; H D Volk; P Reinke
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

6.  Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly.

Authors:  Yuping Deng; Yu Jing; Ann E Campbell; Stefan Gravenstein
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

7.  Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.

Authors:  S Chidrawar; N Khan; W Wei; A McLarnon; N Smith; L Nayak; P Moss
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

8.  In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

9.  New advances in CMV and immunosenescence.

Authors:  Paolo Sansoni; Rosanna Vescovini; Francesco F Fagnoni; Arne Akbar; Ramon Arens; Yen-Ling Chiu; Luka Cičin-Šain; Julie Dechanet-Merville; Evelyna Derhovanessian; Sara Ferrando-Martinez; Claudio Franceschi; Daniela Frasca; Tamas Fulöp; David Furman; Effrossyni Gkrania-Klotsas; Felicia Goodrum; Beatrix Grubeck-Loebenstein; Mikko Hurme; Florian Kern; Daniele Lilleri; Miguel López-Botet; Andrea B Maier; Thomas Marandu; Arnaud Marchant; Catharina Matheï; Paul Moss; Aura Muntasell; Ester B M Remmerswaal; Natalie E Riddell; Kathrin Rothe; Delphine Sauce; Eui-Cheol Shin; Amanda M Simanek; Megan J Smithey; Cecilia Söderberg-Nauclér; Rafael Solana; Paul G Thomas; Rene van Lier; Graham Pawelec; Janko Nikolich-Zugich
Journal:  Exp Gerontol       Date:  2014-04-03       Impact factor: 4.032

10.  Cytomegalovirus infection modulates the phenotype and functional profile of the T-cell immune response to mycobacterial antigens in older life.

Authors:  Nadia Terrazzini; Martha Bajwa; Serena Vita; David Thomas; Helen Smith; Rosanna Vescovini; Paolo Sansoni; Florian Kern
Journal:  Exp Gerontol       Date:  2013-12-25       Impact factor: 4.032

View more
  2 in total

1.  CMV immune evasion and manipulation of the immune system with aging.

Authors:  Sarah E Jackson; Anke Redeker; Ramon Arens; Debbie van Baarle; Sara P H van den Berg; Chris A Benedict; Luka Čičin-Šain; Ann B Hill; Mark R Wills
Journal:  Geroscience       Date:  2017-06-24       Impact factor: 7.713

2.  HIV, HCMV and mycobacterial antibody levels: a cross-sectional study in a rural Ugandan cohort.

Authors:  Lisa Stockdale; Stephen Nash; Angela Nalwoga; Lorna Gibson; Hannah Painter; John Raynes; Gershim Asiki; Robert Newton; Helen Fletcher
Journal:  Trop Med Int Health       Date:  2018-12-27       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.